Janssen-Cilag (JNJ) Submits MA to EMA for Canagliflozin, Metformin in Type 2 Diabetes
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $144.77 +0.22%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 3.4%
Revenue Growth %: -13.4%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 3.4%
Revenue Growth %: -13.4%
Join SI Premium – FREE
Janssen-Cilag International NV (Janssen), a unit of Johnson & Johnson (NYSE: JNJ), announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat adult patients with type 2 diabetes.
Canagliflozin is an investigational, oral medication for the treatment of adult patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people without diabetes, which may contribute to elevated glucose levels in the blood.1 Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.2
Metformin is a first-line pharmacotherapy that can be used alone or with other medications, including insulin, to treat type 2 diabetes. In people with type 2 diabetes, the liver overproduces glucose, which increases blood glucose levels. Metformin lowers blood glucose levels by decreasing the amount of glucose made by the liver, increasing insulin sensitivity in the muscle and delaying intestinal glucose absorption.3
If approved, this canagliflozin/metformin fixed-dose combination therapy could provide convenience for patients who may benefit from two diabetes medications working in one pill.
A significant portion of the clinical data in this MAA are derived from the comprehensive global Phase 3 clinical development programme for canagliflozin, which were included in the MAA for canagliflozin submitted to the EMA on 26 June 2012. The canagliflozin Phase 3 programme represents the largest late-stage development programme for an investigational pharmacologic product for the treatment of patients with type 2 diabetes submitted to health authorities to date.
The Phase 3 programme evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The programme also includes a study in patients who have or are at high risk for developing cardiovascular disease, called the CANagliflozin cardioVascular Assessment Study (CANVAS).
Janssen presented data from Phase 3 studies in 2012 at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHY) in Barcelona in November.
New Drug Applications (NDA) have also been submitted to the U.S. Food and Drug Administration (FDA) for canagliflozin on May 31, 2012 and for a fixed-dose therapy combining canagliflozin and immediate release metformin on December 12, 2012 for the treatment of adult patients with type 2 diabetes.
Janssen is confident in the value of the comprehensive clinical trial programme of canagliflozin supporting the regulatory submissions to the EMA and the FDA. However, the company cannot speculate on the outcome of these regulatory procedures whilst they are ongoing.
Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia.
Canagliflozin is an investigational, oral medication for the treatment of adult patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people without diabetes, which may contribute to elevated glucose levels in the blood.1 Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.2
Metformin is a first-line pharmacotherapy that can be used alone or with other medications, including insulin, to treat type 2 diabetes. In people with type 2 diabetes, the liver overproduces glucose, which increases blood glucose levels. Metformin lowers blood glucose levels by decreasing the amount of glucose made by the liver, increasing insulin sensitivity in the muscle and delaying intestinal glucose absorption.3
If approved, this canagliflozin/metformin fixed-dose combination therapy could provide convenience for patients who may benefit from two diabetes medications working in one pill.
A significant portion of the clinical data in this MAA are derived from the comprehensive global Phase 3 clinical development programme for canagliflozin, which were included in the MAA for canagliflozin submitted to the EMA on 26 June 2012. The canagliflozin Phase 3 programme represents the largest late-stage development programme for an investigational pharmacologic product for the treatment of patients with type 2 diabetes submitted to health authorities to date.
The Phase 3 programme evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The programme also includes a study in patients who have or are at high risk for developing cardiovascular disease, called the CANagliflozin cardioVascular Assessment Study (CANVAS).
Janssen presented data from Phase 3 studies in 2012 at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHY) in Barcelona in November.
New Drug Applications (NDA) have also been submitted to the U.S. Food and Drug Administration (FDA) for canagliflozin on May 31, 2012 and for a fixed-dose therapy combining canagliflozin and immediate release metformin on December 12, 2012 for the treatment of adult patients with type 2 diabetes.
Janssen is confident in the value of the comprehensive clinical trial programme of canagliflozin supporting the regulatory submissions to the EMA and the FDA. However, the company cannot speculate on the outcome of these regulatory procedures whilst they are ongoing.
Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ) PT Lowered to $155 at Stifel
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
